Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$124.62B | 12x | -1.9 | HK$42.50 | 11.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.3% Upside | Upgrade to Pro+ | |
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$119.05B | 23.4x | 0.3 | HK$20.35 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.7% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$69.48B | -47.7x | -4.68 | HK$42.60 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$61.17B | 13.6x | 0.19 | HK$3.36 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.7% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$58.39B | 9x | -3.67 | HK$4.99 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$55.37B | -53.5x | 0.48 | HK$65.50 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.1% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$53.49B | 5.3x | -1.65 | HK$17.16 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$49.86B | 15.9x | -0.45 | HK$13.38 | 10.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.6% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$47.78B | 38.6x | -0.71 | HK$27.80 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.1% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$42.33B | 19.8x | 0.78 | HK$11.14 | 12.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.4% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$39.47B | -148.7x | -2.92 | HK$176.60 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.1% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$38.75B | 8.5x | -1.43 | HK$10.48 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$32.83B | 15.9x | -0.53 | HK$12.30 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.5% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$31.29B | 7.4x | -0.73 | HK$4.98 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$28.19B | 6.7x | -1.07 | HK$17.34 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.1% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$26.39B | -18.3x | -3.83 | HK$12.42 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$24.97B | 21.2x | -0.31 | HK$47.50 | 6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.3% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$23.49B | 34.3x | 0.31 | HK$20.20 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$23.41B | 16.5x | -14.53 | HK$25.45 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$22.93B | -71.4x | 7.9 | HK$27.20 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Traditional Chinese Medicine | Hong Kong | Healthcare | Pharmaceuticals | HK$21.86B | 21.6x | -16.73 | HK$4.35 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.4% Upside | Upgrade to Pro+ | |
Shandong Weigao Medical Polymer | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$21.25B | 9.9x | -0.46 | HK$4.66 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.6% Upside | Upgrade to Pro+ | |
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$18.85B | 12.3x | -0.2 | HK$7.82 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.9% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$16.12B | -6.3x | -0.27 | HK$16.46 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$15.79B | 4.8x | 0.17 | HK$8.71 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.8% Upside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$15.62B | -12.9x | 0.09 | HK$6.25 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.8% Upside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$15.02B | 6.2x | 3.23 | HK$4.33 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$14.79B | -54.9x | 0.29 | HK$3.33 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$13.31B | 7.5x | -0.69 | HK$5.70 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.9% Upside | Upgrade to Pro+ | |
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.08B | -3.1x | -0.58 | HK$123.20 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.6% Upside | Upgrade to Pro+ |